statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call...

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation...

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and...

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th...

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr...

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held...

Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Companys chronic hepatitis delta and chronic hepatitis B programs have been accepted for...

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Companys Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The...

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies Brii Biosciences Announces Two...

Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)

Latest Ratings for VIR
 DateFirmActionFromTo Mar 2022BairdUpgradesUnderperformNeutral Dec 2021BairdDowngradesNeutralUnderperform Dec 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Volume	608,690.00
52-Wk High	$14.27
52-Wk Low	$7.61

VIR Vir Biotechnology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals